Thermo Fisher Scientific Phospho-MYH9 (Ser1916) Polyclonal Antibody

Applications

Tested Dilution

Publications

Western Blot (WB)

1:1000

-

Product Specifications

Species Reactivity

Human, Mouse, Rat

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

Phospho-Myosin IIA Heavy Chain (Ser-1916) synthetic peptide (coupled to KLH) corresponding to amino acid residues surrounding Ser-1916 in human myosin IIA heavy chain. This peptide sequence is highly conserved in rat and mouse myosin IIA heavy chain.

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

~1.0 mg/mL

Purification

Antigen affinity chromatography

Storage buffer

PBS with 1mg/mL BSA, 50% glycerol

Contains

0.05% sodium azide

Storage conditions

-20° C, Avoid Freeze/Thaw Cycles

Shipping conditions

Wet ice

RRID

AB_2942947

Product Specific Information

This antibody was cross-adsorbed to unphosphorylated Myosin IIA Heavy Chain (Ser-1916) peptide before affinity purification using phospho-Myosin IIA Heavy Chain (Ser-1916) peptide (without carrier). The antibody detects a 200 kDa* protein corresponding to Myosin IIA Heavy Chain on SDS-PAGE immunoblots of human A431 cells treated with Calyculin A. This reactivity is removed after treatment with lambda phosphatase.

Target Information

The MYH9 gene, located on chromosome 22q12.3, encodes the heavy chain of non-muscle myosin IIA (NMHC IIA), a critical component of the actin cytoskeleton that plays essential roles in various cellular processes. Structurally, the MYH9 gene spans over 106 kilobases and includes 41 exons that translate into a protein of 1,960 amino acids. This protein is a part of a hexameric complex, which includes two heavy chains, two regulatory light chains, and two essential light chains. The NMHC IIA protein interacts with actin filaments and is involved in cellular activities such as cell migration, adhesion, division, and maintenance of cell shape. Functionally, mutations in MYH9 can result in a spectrum of autosomal dominant disorders collectively known as MYH9-related diseases (MYH9-RD), which include conditions such as May-Hegglin anomaly, Fechtner syndrome, and Epstein syndrome. These disorders are primarily characterized by macrothrombocytopenia (abnormally large platelets) and may lead to other complications such as hearing loss, renal failure, and cataracts later in life. MYH9 is also crucial in hematopoiesis, where its proper function is necessary for the survival and maintenance of hematopoietic stem and progenitor cells (HSPCs). Loss of MYH9 function disrupts normal hematopoiesis, leading to severe blood cell deficiencies and bone marrow failure.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.